On a day of competing earnings calls by the two leaders in the immuno-oncology space, Bristol-Myers Squibb Co. did not back down from the challenge being posed by Merck & Co. Inc. and its PD-1 inhibitor Keytruda (pembrolizumab), as well as that company’s efforts to establish PD-L1 expression as an efficacy biomarker.
Bristol execs told the firm’s April 28 first quarter earnings call that Opdivo (nivolumab) is on pace for success, despite disappointing first quarter sales of $40 million. Keytruda notched sales...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?